Keguan Chen

Statistics

Publications

Citations

192

H-Index

Active since

2002

Affiliations

GlaxoSmithKline (United States)(Current)

Age UK

GlaxoSmithKline (United Kingdom)

Keguan Chen is an author at GlaxoSmithKline (United States) specializing in oncology, immunogenicity of therapeutic antibodies, and monoclonal antibody therapy.

Publications per year

2002–2018

Publications

Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF‐I and EGF

Christina A. LeBedis, Keguan Chen, Lucia Fallavollita et al. · International Journal of Cancer · 2002 · 85 citations · Full text

Medicine, Cell Biology, Oncology +17

Anti‐IL‐7 receptor α monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double‐blind, placebo‐controlled study

Joanne Ellis, André van Maurik, Léa Fortunato et al. · British Journal of Clinical Pharmacology · 2018 · 44 citations · Full text

Pharmacy, Immunology, Pharmacology +16

False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay

Keguan Chen, Jerry G. Page, Ann Schwartz et al. · Journal of Immunological Methods · 2013 · 33 citations

Life Sciences, Immunology, Oncology +14

A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of18F-FB-A20FMDV2 for Imaging the Integrin αvβ6

Nicholas Keat, Julia Kenny, Keguan Chen et al. · Journal of Nuclear Medicine Technology · 2018 · 30 citations · Full text

Medicine, Nuclear Medicine, Radiology +16

1–4 of 4